secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2026-05-12T11:30:18+00:00
Accession:  0001171843-26-003270
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q1 revenue $20.8M, gross margin 59%; reaffirms FY guidance
-----------------------------------------------------------------------------

- Revenue $20.8M (down 5% YoY from $21.8M); net loss $(3.4)M vs $(50.3)M including $48M impairment.
- Gross margin 59% (vs 56% prior year); driven by higher-margin NPI mix (MeshMEA, BTX, SoHo).
- Adjusted EBITDA $0.8M flat YoY; cash used in ops $(0.7)M vs $3.0M in Q1 2025.
- Reaffirms full-year 2026 guidance; manufacturing consolidation on track for efficiencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326003270/0001171843-26-003270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326003270/f8k_050826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer